Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT6EO5L)

• DTT Name: Erbb2 tyrosine kinase receptor (HER2) DTT Info
• Gene Name: ERBB2

Molecule-Related Drug & Molecule List

10 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[1]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[2]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[3]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[4]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[5]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[6]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[7]
Pertuzumab	DMHJV0X	Adrenal gland neoplasm		Approved	[8]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[9]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[10]

74 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HKI-272	DM6QOVN	Breast cancer	2C60-2C65	Phase 3	[11]
Nelipepimut S	DMDBY30	Non-hodgkin lymphoma	2B33.5	Phase 3	[12]
NeuVax	DMYTC4I	Breast cancer	2C60-2C65	Phase 3	[12]
PF-05280014	DM23BUP	Breast cancer	2C60-2C65	Phase 3	[13]
SYD985	DM0JC9L	Breast cancer	2C60-2C65	Phase 3	[14]
Taxol/Paraplatin/Herceptin	DML6GAN	Breast cancer	2C60-2C65	Phase 3	[15]
Trastuzumab-DM1	DMLB3I4	Breast cancer	2C60-2C65	Phase 3	[16]
Varlitinib	DMDG8Q3	Metastatic biliary tract neoplasms	2C14-2C17	Phase 2/3	[17]
Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells	DMPRIHK	Breast cancer	2C60-2C65	Phase 2	[18]
AZD8931	DMFLCW4	Breast cancer	2C60-2C65	Phase 2	[19]
BMS-599626	DMDPQV5	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[11]
CP-724714	DMUJ0W7	Lymphoma	2A80-2A86	Phase 2	[11]
DN24-02	DM725UG	Colorectal cancer	2B91.Z	Phase 2	[20]
Ertumaxomab	DM5Z3VP	Breast cancer	2C60-2C65	Phase 2	[21]
HER-2 Protein AutoVac	DM8TOS0	Breast cancer	2C60-2C65	Phase 2	[22]
Her2-targeted autologous T-cell therapy	DMQTREC	Glioblastoma multiforme	2A00.0	Phase 2	[23]
HER2/neu peptide vaccine	DMISETH	Breast cancer	2C60-2C65	Phase 2	[24]
HM-78136B	DMZ3BER	HER2-positive breast cancer	2C60-2C65	Phase 2	[25]
KN026	DMNLH9W	Breast cancer	2C60-2C65	Phase 2	[26]
MCLA-128	DM0W3R7	Breast cancer	2C60-2C65	Phase 2	[27]
MGAH22	DMIXT2Y	Solid tumour/cancer	2A00-2F9Z	Phase 2	[28]
MM-111	DMO7MBS	Breast cancer	2C60-2C65	Phase 2	[29]
MRG002	DMJK8L1	Urothelial carcinoma	2C92.0	Phase 2	[30]
Tarloxotinib	DMA7ISF	Non-small-cell lung cancer	2C25.Y	Phase 2	[31]
Zenocutuzumab	DM1FLHH	Pancreatic cancer	2C10	Phase 2	[32]
A166	DMGTOIX	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[33]
ABY-025	DM31NJU	Bladder cancer	2C94	Phase 1/2	[34]
AGN-208397	DMHZUF8	Retina venous occlusion	9B74.1	Phase 1/2	[35]
Anti-HER2 CAR-T	DMQD6B9	Colorectal cancer	2B91.Z	Phase 1/2	[36]
AU105	DMPAZ3U	Recurrent glioblastoma	2A00.00	Phase 1/2	[37]
AVX901	DM7O29W	Breast cancer	2C60-2C65	Phase 1/2	[38]
BDTX-189	DMODTX5	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[39]
CART-HER-2	DMMTDK1	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[40]
HER-2-targeting CAR T Cells	DM1U6VX	Breast cancer	2C60-2C65	Phase 1/2	[41]
ISB 1302	DM1WD8F	HER2-positive breast cancer	2C60-2C65	Phase 1/2	[42]
Sym013	DMZM6I2	Epithelial ovarian cancer	2B5D	Phase 1/2	[27]
TAS-0728	DM13AH8	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[43]
Zenocutuzomab	DMMQGPE	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[44]
S-222611	DMQGH76	Malignant solid tumour	2C10-2F32	Phase 1b	[45]
ACE1702	DMHI7DX	Aggressive cancer	2A00-2F9Z	Phase 1	[46]
AIP-303	DMHCBI0	Breast cancer	2C60-2C65	Phase 1	[47]
ARRY-380	DMCNV0M	Solid tumour/cancer	2A00-2F9Z	Phase 1	[48]
BAY 2701439	DM98EP5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[49]
BB-1701	DMOAK6T	Aggressive cancer	2A00-2F9Z	Phase 1	[50]
CAR-T cells targeting HER2	DMLI5VG	Pancreatic cancer	2C10	Phase 1	[51]
Cipatinib	DMJLNEF	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
CUDC-101	DM9ZOMD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[52]
DZD1516	DMEQY4Z	HER2-positive breast cancer	2C60-2C65	Phase 1	[53]
GBR1302	DM52O7W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[54]
GQ1001	DMFA2XQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[55]
HER2-CAR T Cells	DMZXDBN	Malignant neoplasm	2A00-2F9Z	Phase 1	[56]
HER2-specific CAR T cell	DMJKBWO	Atypical teratoid/rhabdoid tumour	2A00.1Y	Phase 1	[57]
HER2-specific T cells	DM7UJ6E	Recurrent glioblastoma	2A00.00	Phase 1	[58]
HER2p63-71 peptide vaccine	DMJ52F9	Solid tumour/cancer	2A00-2F9Z	Phase 1	[59]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[60]
M802	DM132EG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[61]
MB-103	DMS0P5O	Glioblastoma multiforme	2A00.0	Phase 1	[62]
MBS301	DM85AXS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[63]
MEDI4276	DMNI60O	Solid tumour/cancer	2A00-2F9Z	Phase 1	[27]
MM-302	DMYSJTR	Breast cancer	2C60-2C65	Phase 1	[64]
MT-5111	DM5SN0A	Solid tumour/cancer	2A00-2F9Z	Phase 1	[65]
MVA HER-2 AutoVac	DM3JUXW	Breast cancer	2C60-2C65	Phase 1	[66]
NJH395	DMSENTW	HER2-positive metastatic breast cancer	2C60-2C65	Phase 1	[67]
Recombinant human Erbb3 fragment therapeutic tumor vaccine	DMK9Y71	Solid tumour/cancer	2A00-2F9Z	Phase 1	[68]
Runimotamab	DML6BK5	Breast cancer	2C60-2C65	Phase 1	[69]
SAR443216	DMUQNG6	Gastric cancer	2B72	Phase 1	[70]
SBT6050	DMHBD3T	Solid tumour/cancer	2A00-2F9Z	Phase 1	[71]
TAK-285	DM6KOBZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[72]
TrasGEX	DMMRDUN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[73]
TT16	DM5YL4N	Aggressive cancer	2A00-2F9Z	Phase 1	[74]
VM-206	DMB3I04	Solid tumour/cancer	2A00-2F9Z	Phase 1	[75]
Zemab	DM2S04R	Solid tumour/cancer	2A00-2F9Z	Phase 1	[76]
ZW49	DMAU8L9	Solid tumour/cancer	2A00-2F9Z	Phase 1	[77]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Her-2-Bi-armed ATC	DM5JZW2	Breast cancer	2C60-2C65	Discontinued in Phase 2	[78]
TAK165	DMBE5OF	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[11]
GW-974	DMPLYHU	Breast cancer	2C60-2C65	Terminated	[80]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
227Th-labelled HER2-TTC	DM1O2C3	Solid tumour/cancer	2A00-2F9Z	Preclinical	[79]

6 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine	DMNIP7J	Discovery agent	N.A.	Investigative	[81]
(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine	DM0SCW9	Discovery agent	N.A.	Investigative	[81]
PF 5208766	DMY45K1	Discovery agent	N.A.	Investigative	[82]
Redoxal	DM2S496	Discovery agent	N.A.	Investigative	[83]
TA1-RTA	DMP2016	Discovery agent	N.A.	Investigative	[84]
YH012	DMG3WBJ	Aggressive cancer	2A00-2F9Z	Investigative	[85]

References

• [1] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
• [3] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [7] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [8] Clinical pipeline report, company report or official report of Roche (2009).
• [9] Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [11] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [12] The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31.
• [13] Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin( )). BioDrugs. 2014 Oct;28(5):451-9.
• [14] Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem. 2019 Dec 1;183:111682.
• [15] Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32.
• [16] Clinical pipeline report, company report or official report of Genentech (2009).
• [17] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [18] Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res. 2001 Apr;10(2):247-60.
• [19] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [20] Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007 Aug 20;25(24):3680-7.
• [21] Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
• [22] Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32.
• [23] A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res. 2014;2014:326545.
• [24] N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. Anticancer Res. 2009 Jul;29(7):2427-35.
• [25] Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54.
• [26] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [27] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [28] Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res. 2011; 13(6): R123.
• [29] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [30] ClinicalTrials.gov (NCT04839510) A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer. U.S. National Institutes of Health.
• [31] Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475.
• [32] Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12(5):1233-1247.
• [33] Clinical pipeline report, company report or official report of KLUS Pharma.
• [34] Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010 Jul;51(7):1131-8.
• [35] New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2.
• [36] ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
• [37] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [38] ClinicalTrials.gov (NCT01526473) A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901. U.S. National Institutes of Health.
• [39] Clinical pipeline report, company report or official report of Black Diamond Therapeutics.
• [40] ClinicalTrials.gov (NCT01935843) Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors
• [41] ClinicalTrials.gov (NCT02547961) Chimeric Antigen Receptor-Modified T Cells for Breast Cancer
• [42] Clinical pipeline report, company report or official report of Ichnos Sciences.
• [43] TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2019 Apr;18(4):733-742.
• [44] Clinical pipeline report, company report or official report of Merus.
• [45] Clinical pipeline report, company report or official report of Shionogi (2011).
• [46] A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology. Cancers (Basel). 2021 May 31;13(11):2724.
• [47] Clinical pipeline report, company report or official report of Adagene.
• [48] ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2, Increases Survival in Intracranial ErbB2+ Xenograft Models in Mice
• [49] National Cancer Institute Drug Dictionary (drug name BAY2701439).
• [50] ClinicalTrials.gov (NCT04257110) A First-in-human, Open Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors. U.S.National Institutes of Health.
• [51] ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
• [52] A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
• [53] ClinicalTrials.gov (NCT04509596) DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer. U.S. National Institutes of Health.
• [54] Clinical pipeline report, company report or official report of Glenmark Pharmaceuticals.
• [55] Clinical pipeline report, company report or official report of GeneQuantum Healthcare.
• [56] ClinicalTrials.gov (NCT03696030) HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases
• [57] ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
• [58] ClinicalTrials.gov (NCT02442297) T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma
• [59] Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother Pharmacol. 2000;46 Suppl:S77-82.
• [60] National Cancer Institute Drug Dictionary (drug id 596693).
• [61] A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019 Aug 14;38(1):355.
• [62] Clinical pipeline report, company report or official report of Mustang Bio.
• [63] Clinical pipeline report, company report or official report of Beijing Mabworks Biotech.
• [64] Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates. EJNMMI Res. 2015 Apr 14;5:24.
• [65] Clinical pipeline report, company report or official report of Molecular Templates.
• [66] Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol. 2013 Jul;24(7):1740-8.
• [67] ClinicalTrials.gov (NCT03696771) Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer. U.S. National Institutes of Health.
• [68] Clinical pipeline report, company report or official report of Zensun.
• [69] ClinicalTrials.gov (NCT03448042) A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers. U.S. National Institutes of Health.
• [70] Clinical pipeline report, company report or official report of Sanofi
• [71] Clinical pipeline report, company report or official report of Silverback Therapeutics.
• [72] Clinical pipeline report, company report or official report of Takeda (2009).
• [73] J Clin Oncol 32:5s, 2014 (suppl; abstr 2515).
• [74] Clinical pipeline report, company report or official report of Tessa Therapeutics
• [75] WO patent application no. 2014,1441,21, Classification and actionability indices for lung cancer.
• [76] Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. Toxins (Basel) 2011 July; 3(7): 848-883.
• [77] Clinical pipeline report, company report or official report of Zymeworks.
• [78] Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther. 2010 June; 12(3): 340-349.
• [79] Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
• [80] WO patent application no. 2005,0443,02, Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer.
• [81] Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
• [82] Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor... J Med Chem. 2005 Feb 24;48(4):1107-31.
• [83] A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res. 2002 Jun;8(6):1710-9.
• [84] Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res.2000 Aug;6(8):3334-41.
• [85] Clinical pipeline report, company report or official report of Biocytogen